Thank you ! That explains what I was missing . So any higher event rates in our placebo group may br due to low Hdl and that half our on drug group is on Crestor which was unlikely back in Examine days when Atorvastatin was the Standard ? A factor that could lower all rates may be better Standard of care these days ? Your help is very much appreciated and glad RVX took all this into account up front, as well as RVX’s own previous data on low Hdl and Crestor patients which should skew thing nicely in our favor, no ?
